VBI Vaccines Inc. (VBIV) and Otonomy Inc. (NASDAQ:OTIC) Contrasting side by side

VBI Vaccines Inc. (NASDAQ:VBIV) and Otonomy Inc. (NASDAQ:OTIC) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VBI Vaccines Inc. 3.35M 55.31 63.60M -0.90 0.00
Otonomy Inc. N/A 113.27 50.37M -1.85 0.00

Table 1 shows the gross revenue, earnings per share and valuation for VBI Vaccines Inc. and Otonomy Inc.


Table 2 shows the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
VBI Vaccines Inc. -1,898.51% 0% 0%
Otonomy Inc. 0.00% -54.2% -49.5%

Analyst Recommendations

The Recommendations and Ratings for VBI Vaccines Inc. and Otonomy Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
VBI Vaccines Inc. 0 0 1 3.00
Otonomy Inc. 0 0 1 3.00

$9 is VBI Vaccines Inc.’s average price target while its potential upside is 373.68%. Competitively Otonomy Inc. has a consensus price target of $5, with potential upside of 81.82%. The results from earlier shows that analysts view suggest that VBI Vaccines Inc. seems more appealing than Otonomy Inc.

Institutional & Insider Ownership

The shares of both VBI Vaccines Inc. and Otonomy Inc. are owned by institutional investors at 55.46% and 66.1% respectively. About 11.91% of VBI Vaccines Inc.’s share are held by insiders. Comparatively, insiders own roughly 0.29% of Otonomy Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
VBI Vaccines Inc. 8.29% 17.37% 20.25% -2.97% -48.69% 22.5%
Otonomy Inc. 8.22% 16.75% 1.72% -22.3% -58.05% 28.11%

For the past year VBI Vaccines Inc. has weaker performance than Otonomy Inc.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. OTIPRIO has also completed a Phase III clinical trial for treating swimmer’s ear and a Phase II clinical trial for treating acute otitis media with tubes. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.